Related Experiment Video
Updated: Feb 14, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Why target PIM1 for cancer diagnosis and treatment?
Nancy S Magnuson1, Zeping Wang, Gang Ding
1School of Molecular Biosciences, Washington State University, Pullman, WA 99164–7520, USA.
Abstract:
The highly conserved proto-oncogenic protein PIM1 is an unusual serine or threonine kinase, in part because it is constitutively active. Overexpression of PIM1 experimentally leads to tumor formation in mice, while complete knockout of the protein has no observable phenotype. It appears to contribute to cancer development in three major ways when it is overexpressed; by inhibiting apoptosis, by promoting cell proliferation and by promoting genomic instability. Expression in normal tissues is nearly undetectable. However, in hematopoietic malignancies and in a variety of solid tumors, increased PIM1 expression has been shown to correlate with the stage of disease. This characteristic suggests it can serve as a useful biomarker for cancer diagnosis and prognosis. Several specific and potent inhibitors of PIM1’s kinase activity have also been shown to induce apoptotic death of cancer cells, to sensitize cancer cells to chemotherapy and to synergize with other anti-tumor agents, thus making it an attractive therapeutic target.
Insights
Proto-oncogenic PIM1 kinase, though not essential for normal function, drives cancer by inhibiting apoptosis, promoting proliferation, and genomic instability. PIM1 inhibitors show therapeutic promise for various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- PIM1 is a highly conserved, constitutively active serine/threonine kinase.
- Overexpression of PIM1 is linked to tumor formation, while its absence has no observable phenotype.
- PIM1's role in cancer involves inhibiting apoptosis, promoting cell proliferation, and genomic instability.
Purpose of the Study:
- To explore the role of PIM1 in cancer development and its potential as a biomarker and therapeutic target.
- To investigate the mechanisms by which PIM1 contributes to oncogenesis.
- To evaluate the therapeutic potential of PIM1 kinase inhibitors.
Main Methods:
- Analysis of PIM1 expression in normal tissues versus various tumors.
- Experimental induction of PIM1 overexpression in mice to study tumor formation.
- Assessment of PIM1 inhibitors' effects on cancer cell apoptosis, proliferation, and chemosensitivity.
Main Results:
- PIM1 expression is typically undetectable in normal tissues but elevated in hematopoietic malignancies and solid tumors.
- Increased PIM1 expression correlates with disease stage, suggesting biomarker potential.
- PIM1 inhibitors induce cancer cell apoptosis, enhance chemotherapy sensitivity, and synergize with other anti-cancer agents.
Conclusions:
- PIM1 is a proto-oncogenic kinase that significantly contributes to cancer development through multiple mechanisms.
- PIM1's elevated expression in tumors and its role in cancer progression make it a valuable diagnostic and prognostic biomarker.
- Targeting PIM1 kinase activity with specific inhibitors represents a promising therapeutic strategy for cancer treatment.
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22Nursing Diagnosis
The nursing diagnosis focuses on evidence-based...
01:26Formulating and Validating Nursing Diagnosis I
There are thirteen domains...
01:10Documentation of Nursing Diagnosis
In some settings, data-driven computerized decision support systems are in place, allowing for more accurate nursing diagnoses. The database within one of these systems includes diagnostic labels defining characteristics, activities, and indicators for nursing. A nurse enters...
01:25Formulating and Validating Nursing Diagnosis II
Risk nursing diagnoses represent clinical judgments of an individual, family, or community more vulnerable to developing the health problem than others...